title: Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag').
abstract: Reduced-intensity conditioning (RIC) has allowed the use of allogeneic stem cell transplantation (alloSCT) for haematological malignancies in elderly patients. A major problem of this type of transplantation is the high incidence of persisting chronic graft-versus-host disease (GvHD), leading to increased morbidity and mortality. The inclusion of alemtuzumab added to the graft ('Campath in the bag') for donor T-cell depletion offers an easy procedure to diminish the incidence of GvHD. Good engraftment is observed in most patients, whereas almost no GvHD is observed after transplantation. Most patients become mixed chimeric after transplantation, requiring donor lymphocyte infusion for conversion to full donor chimerism. Although subsequent acute and chronic GvHD is observed in 50-60% of patients, it is responsive to therapy in many patients, resulting in a low incidence of persisting chronic GvHD. AlloSCT with RIC and alemtuzumab-induced T-cell depletion offers a suitable platform for the investigation of novel cellular immunotherapy.
authors: Department of Hematology C2-R, Leiden University Medical Center, Leiden, The Netherlands. P.A.von_dem_Borne@lumc.nl
authors: Peter A
authors: PA
authors: von dem Borne
authors: C W J Ingrid
authors: CW
authors: Starrenburg
authors: Stijn J M
authors: SJ
authors: Halkes
authors: W A Erik
authors: WA
authors: Marijt
authors: Willem E
authors: WE
authors: Fibbe
authors: J H Frederik
authors: JH
authors: Falkenburg
authors: Roel
authors: R
authors: Willemze
mesh_terms: D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D006086:Graft vs Host Disease / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D006801:Humans; D007938:Leukemia / Q000378:metabolism / Q000628:therapy; D008212:Lymphocyte Depletion; D008875:Middle Aged; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab